Clinical-stage biotechnology company focused on developing next-generation radiopharmaceutical therapies for prostate cancer
Location: United States, Massachusetts, Cambridge
Investors 1
| Date | Name | Website |
| 30.08.2023 | OrbiMed | orbimed.co... |
Mentions in press and media 3
| Date | Title | Description |
| 26.09.2024 | Convergent Therapeutics: $40 Million (Series A Extension) Secured From Novo | Convergent Therapeutics Inc., a clinical stage biotechnology company focused on developing next generation radiopharmaceutical therapies for the treatment of prostate cancer and other cancers, announced that the first patient has been dosed... |
| 03.05.2023 | Convergent Therapeutics Raises $90M in Series A Funding | Convergent Therapeutics, a Cambridge, MA-based clinical-stage biotechnology company, raised $90M in Series A funding. The round was led by OrbiMed and RA Capital Management with participation from Invus. The company intends to use the funds... |
| - | Convergent Therapeutics | “Convergent Therapeutics – Next-Gen Targeted Radiotherapies” |